Psychedelics are getting their moment in the spotlight as a mental health treatment option with the White House recently issuing an executive order accelerating psychedelic research and access.

Mental illness costs the U.S. economy more than $280 billion annually, drives veteran suicide rates, and places mounting strain on everything from emergency rooms to the workforce.

On May 19, join The Hill, in partnership with Definium Therapeutics, for a timely mental health policy forum.

SPEAKER HIGHLIGHTS:

Rep. Jack Bergman (R-Mich.), Co-Chair & Co-Founder, Congressional Psychedelics Advancing Therapies Caucus & Member, Veterans Affairs Committee
Dr. Michael Davis, Deputy Center Director, Center for Drug Evaluation & Research (CDER), Food & Drug Administration (FDA)
John Eaton, Vice President, Complex Care, Wounded Warrior Project (WWP)
Mary Giliberti, Chief Public Policy Officer, Mental Health America
Matthew Strait, Former Drug Enforcement Administration (DEA) Official & Principal, Controlled Substance Strategies
Stephanie Fagan, Chief Corporate Affairs Officer, Definium Therapeutics

Event Details
Date: Tuesday, May 19
Program begins: 8:30 a.m ET
Program concludes: 10:00 a.m ET

Location: Washington, D.C., and streaming nationwide

Recommend The Hill's newsletters to a friend: TheHill.com/signup.

400 N Capitol Street NW Suite 650, Washington, DC 20001

To ensure you receive these emails in the future, please add
thehill@email.thehill.com to your address book, contacts or safe senders list.

If you believe this has been sent to you in error, please safely unsubscribe.